{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:15:43Z","timestamp":1787595343894,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Magnesium sulfate is a second-tier therapy for asthma exacerbations in children; guidelines recommend a single-dose to improve pulmonary function and decrease the odds of admission to the in-patient setting. However, many clinicians utilize prolonged magnesium sulfate infusions for children with refractory asthma. The purpose of this review is to describe the efficacy and safety of magnesium sulfate infusions administered over \u2265 1 h in children with status asthmaticus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medline was searched using the keywords \u201cmagnesium sulfate\u201d and \u201cchildren.\u201d Articles evaluating the use of magnesium sulfate infusions for \u22651 h published between 1946 and August 2021 were included. Published abstracts were not included because of lack of essential details. All articles were screened by two reviewers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight reports including 447 children were included. The magnesium regimens evaluated included magnesium delivered over 1 h (<jats:italic>n<\/jats:italic> = 148; 33.1%), over 4\u20135 h (<jats:italic>n<\/jats:italic> = 105; 23.5%), and over &amp;gt;24 h (<jats:italic>n<\/jats:italic> = 194; 43.4%). Majority of patients received a bolus dose of 25\u201375 mg\/kg\/dose prior to initiation of a prolonged infusion (<jats:italic>n<\/jats:italic> = 299; 66.9%). For the patients receiving magnesium infusions over 4\u20135 h, the dosing regimen varied between 40 and 50 mg\/kg\/h. For those receiving magnesium infusions &amp;gt;24 h, the dosing varied between 18.4 and 25 mg\/kg\/h for a duration between 53.4 and 177.5 h. Only three reports including 186 patients (41.6%) included an evaluation of clinical outcomes including evaluation of lung function parameters, reduction in PICU transfers, and\/or decrease in emergency department length of stay. Five reports including 261 patients (58.4%) evaluated magnesium serum concentrations. In most reports, the goal concentrations were between 4 and 6 mg\/dL. Only 3 (1.1%) out of the 261 patients had supratherapeutic magnesium concentrations. The only reports finding adverse events attributed to magnesium were noted in those receiving infusions for &amp;gt;24 h. Clinically significant adverse events included hypotension (<jats:italic>n<\/jats:italic> = 74; 16.6%), nausea\/vomiting (<jats:italic>n<\/jats:italic> = 35; 7.8%), mild muscle weakness (<jats:italic>n<\/jats:italic> = 22; 4.9%), flushing (<jats:italic>n<\/jats:italic> = 10; 2.2%), and sedation (<jats:italic>n<\/jats:italic> = 2; 0.4%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Significant variability was noted in magnesium dosing regimens, with most children receiving magnesium infusions over &amp;gt;4 h. Most reports did not assess clinical outcomes. Until future research is conducted, the use of prolonged magnesium sulfate infusions should be reserved for refractory asthma therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.853574","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T22:08:27Z","timestamp":1648418907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Continuous Magnesium Sulfate Infusions for Status Asthmaticus in Children: A Systematic Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Peter N.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Sahlstrom","family":"Drury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","first-page":"1","article-title":"Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010.","volume":"94","author":"Akinbami","year":"2012","journal-title":"NCHS Data Brief."},{"key":"B2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4187\/respcare.07944","article-title":"Implementation of a critical asthma protocol in a pediatric ICU.","volume":"66","author":"Kucher","year":"2021","journal-title":"Respir Care."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group.","volume":"146","author":"Cloutier","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.jaci.2007.09.043","article-title":"Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007.","volume":"120","year":"2007","journal-title":"J Allergy Clin Immunol."},{"key":"B5","year":"2021","journal-title":"Global Strategy for Asthma Management and Prevention."},{"key":"B6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5863\/1551-6776-18.2.88","article-title":"Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.","volume":"18","author":"Nievas","year":"2013","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00228-016-2165-3","article-title":"Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma.","volume":"73","author":"Rower","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/PEC.0000000000000909","article-title":"Intravenous and nebulized magnesium sulfate for treating acute asthma in children: a systematic review and meta-analysis.","volume":"34","author":"Su","year":"2018","journal-title":"Pediatr Emerg Care."},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD011050","DOI":"10.1002\/14651858.CD011050.pub2","article-title":"Intravenous magnesium sulfate for treating children with acute asthma in the emergency department.","volume":"4","author":"Griffiths","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/etm.2016.3912","article-title":"Effects of salbutamol aerosol combined with magnesium sulfate on T-lymphocyte subgroup and Th1\/Th2 cytokines of pediatric asthma.","volume":"13","author":"Diao","year":"2017","journal-title":"Exp Ther Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/ppul.24013","article-title":"The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting.","volume":"53","author":"DeSanti","year":"2018","journal-title":"Pediatr Pulmonol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000506595","article-title":"Efficacy of magnesium sulfate treatment in children with acute asthma.","volume":"29","author":"\u00d6zdemir","year":"2020","journal-title":"Med Princ Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5863\/1551-6776-17.2.150","article-title":"Feasibility of short-term infusion of magnesium sulfate in pediatric patients with status asthmaticus.","volume":"17","author":"Irazuzta","year":"2012","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00134-012-2734-6","article-title":"High-dose magnesium sulfate infusion protocol for status asthmaticus: a safety and pharmacokinetics cohort study.","volume":"39","author":"Egelund","year":"2013","journal-title":"Intensive Care Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5863\/1551-6776-21.3.233","article-title":"Comparison of two high-dose magnesium infusion regimens in the treatment of status asthmaticus.","volume":"21","author":"Vaiyani","year":"2016","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/PCC.0000000000000581","article-title":"High-dose magnesium sulfate infusion for severe asthma in the emergency department: efficacy study.","volume":"17","author":"Irazuzta","year":"2016","journal-title":"Pediatr Crit Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/jcrc.2002.36759","article-title":"Magnesium sulfate administered via continuous intravenous infusion in pediatric patients with refractory wheezing.","volume":"17","author":"Glover","year":"2002","journal-title":"J Crit Care."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ppul.24499","article-title":"Safety of prolonged magnesium sulfate infusions during treatment for severe pediatric status asthmaticus.","volume":"54","author":"Graff","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2146\/ajhp160005","article-title":"Assessment of inpatient admissions and top 25 medications for obese pediatric patients at two academic hospitals.","volume":"73","author":"Johnson","year":"2016","journal-title":"Am J Health Syst Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jpeds.2020.01.062","article-title":"Intravenous magnesium in asthma pharmacotherapy: variability in use in the PECARN registry.","volume":"220","author":"Johnson","year":"2020","journal-title":"J Pediatr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/AOG.0b013e31827d90cc","article-title":"Effect of maternal body mass index on serum magnesium levels given for seizure prophylaxis.","volume":"121","author":"Tudela","year":"2013","journal-title":"Obstet Gynecol."},{"key":"B22","author":"Takemoto","year":"2021","journal-title":"Pediatric and Neonatal Dosage Handbook."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/ajhp\/zxz168","article-title":"Pediatric medication safety considerations for pharmacists in an adult hospital setting.","volume":"76","author":"Kennedy","year":"2019","journal-title":"Am J Health Syst Pharm."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.853574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T22:08:32Z","timestamp":1648418912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.853574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":23,"alternative-id":["10.3389\/fped.2022.853574"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.853574","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"853574"}}